VIOLIN: Vaccine Investigation and Online Information Network

Bcr-abl peptide vaccine

Vaccine Information

Vaccine Name: Bcr-abl peptide vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007400
Type: Subunit vaccine
Status: Clinical trial
Host Species for Licensed Use: None
Antigen: bcr-abl oncogene breakpoint fusion peptide (NCIT_C2205; NCT00004052; NCT00455221)
Adjuvant: QS21 (NCT00004052) or Cytokine gene adjuvant, IL-12 and GM-CSF plasmids (NCT00455221)
Immunization Route: subcutaneous injection
Description: This is a multivalent antineoplastic vaccine comprised of the bcr-abl oncogene breakpoint fusion peptide that elicits a bcr-abl specific T-cell immune response. (NCIT_C2205) The multivalent tumor-specific breakpoint peptide vaccine in patients with chronic myelogenous leukemia. (NCT00004052) The bcr-abl peptides can be used in combination with IL-12 and GM-CSF plasmids to help treat patients with CML. (NCT00455221)

Host Response

References

NCIT_C2205: BCR-ABL Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205]

NCT00004052: Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia [https://clinicaltrials.gov/study/NCT00004052]

NCT00455221: Safety Assessment of a Multipeptide-gene Vaccine in CML [https://clinicaltrials.gov/study/NCT00455221]